Docoh
Loading...

IMGN Immunogen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

Company profile

Ticker
IMGN
Exchange
CEO
Mark Enyedy
Employees
Incorporated
Location
Fiscal year end
Former names
IMMUNOGEN INC
SEC CIK
IRS number
42726691

IMGN stock data

(
)

Calendar

1 Mar 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Immunogen earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 293.86M 293.86M 293.86M 293.86M 293.86M 293.86M
Cash burn (monthly) (positive/no burn) (positive/no burn) (positive/no burn) 1.87M (positive/no burn) 6.55M
Cash used (since last report) n/a n/a n/a 6.29M n/a 22.1M
Cash remaining n/a n/a n/a 287.56M n/a 271.75M
Runway (months of cash) n/a n/a n/a 154.2 n/a 41.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Mitchell Dean J Deferred Share Unit Common Stock Grant Aquire A No No 0 1,666 0 93,774
31 Mar 21 Goldberg Mark Alan Deferred Share Unit Common Stock Grant Aquire A No No 0 1,666 0 109,876
5 Feb 21 Renee Lentini Common Stock Common Stock Grant Aquire A No No 7.69 80,800 621.35K 80,800
5 Feb 21 Berkenblit Anna Common Stock Common Stock Grant Aquire A No No 7.69 282,019 2.17M 282,019
5 Feb 21 Stacy Ann Coen Common Stock Common Stock Grant Aquire A No No 7.69 185,016 1.42M 185,016

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

86.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 205 183 +12.0%
Opened positions 41 28 +46.4%
Closed positions 19 28 -32.1%
Increased positions 56 47 +19.1%
Reduced positions 72 68 +5.9%
13F shares
Current Prev Q Change
Total value 1.12B 510.8M +118.4%
Total shares 172.9M 141.88M +21.9%
Total puts 465.8K 135K +245.0%
Total calls 451.9K 198.4K +127.8%
Total put/call ratio 1.0 0.7 +51.5%
Largest owners
Shares Value Change
Wellington Management 22.08M $142.44M -4.3%
Ra Capital Management 18.42M $118.79M +161.6%
BLK Blackrock 15.16M $97.76M +10.4%
Vanguard 14.16M $91.31M -0.2%
FMR 12.54M $80.9M +696.8%
Redmile 10.53M $67.91M +0.5%
STT State Street 8.8M $56.79M -1.8%
Clearbridge Advisors 6.89M $44.46M -7.5%
MS Morgan Stanley 4.65M $29.97M +158.7%
Renaissance Technologies 4.24M $27.32M -34.7%
Largest transactions
Shares Bought/sold Change
Ra Capital Management 18.42M +11.38M +161.6%
FMR 12.54M +10.97M +696.8%
Assenagon Asset Management 0 -4.99M EXIT
Consonance Capital Management 3.52M +3.52M NEW
MS Morgan Stanley 4.65M +2.85M +158.7%
Millennium Management 1.95M -2.8M -58.9%
Orbimed Advisors 2.55M +2.55M NEW
Adage Capital Partners GP, L.L.C. 2.48M +2.48M NEW
Renaissance Technologies 4.24M -2.25M -34.7%
GS Goldman Sachs 2.62M +1.69M +180.5%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Academy, accessibility, AgreementSM, Alexion, alter, Altschuller, ample, antileukemia, authoritative, Biden, BIO, Bioverativ, camptothecin, capillary, career, Coen, compendia, CRc, Darden, Enterprise, evergreen, Factoring, folate, graduate, Hangzhou, home, Hong, Huadong, Huntington, interface, intolerance, investor, Kong, leak, linked, LogicBio, Macau, MBA, mortality, NaN, outset, perspective, poster, PR, predetermined, predominantly, prejudice, proportionate, racism, reenacted, relinquishing, Republic, reward, source, Stacy, sublet, Susan, syndrome, synergistic, Taiwan, teen, twenty, Virginia, Viridian, virtual, Wall, weaken, weather, workplace, xenograft, Zhongmei
Removed: affiliate, aggregating, alternatively, anniversary, assured, batch, Bermuda, book, build, cancelled, choice, collectability, commanding, commensurate, compare, comparing, conservative, Cowen, creation, crosslinking, deliverable, discounted, discover, DMx, documented, doxorubicin, element, eligibility, enabling, enhancement, equally, establishment, expensing, feature, finalized, flexibility, forego, foundation, GCC, inauguration, indatuximab, input, invalidated, lab, lieu, liposomal, long, maximum, medium, mid, mitigated, optioned, paclitaxel, pegylated, pembrolizumab, PFS, placement, plant, predicated, preferred, preparing, privately, profit, prompt, ran, reclassed, recognizable, referenced, Reinvestment, reliably, replace, replaced, retrospectively, revaluation, revalue, revert, segregate, shipped, short, SPA, statistical, strong, subset, TCJA, tenant, thereunder, topotecan, triple, unaudited, undelivered, underway, unilateral, unrecognizable, waive, weekly, wide

Patents

APP
Utility
Selective Sulfonation of Benzodiazepine Derivatives
8 Apr 21
The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group.
GRANT
Utility
Methods of preparing substituted 12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indoles
6 Apr 21
Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
APP
Utility
Conjugates of Cysteine Engineered Antibodies
25 Mar 21
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA.
APP
Utility
Camptothecin Derivatives
18 Mar 21
Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents.
GRANT
Utility
Benzodiazepine derivatives
16 Mar 21
The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic.